Pabolizumab and karelizumab are both PD-1 monoclonal antibody immunotherapeutic drugs, differing in whether they are imported drugs, approved indications and price. Pabrolizumab is an imported PD-1 agent, malignant tumor immunotherapy drug, the main indications include for the treatment of melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, colorectal cancer, the price of a single is about 15,000 yuan. Karelizumab is a domestic PD-1 agent, malignant tumor immunotherapy drugs, the main indications include for the treatment of non-small cell lung cancer, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, hepatocellular carcinoma, classic Hodgkin’s lymphoma, included in the medical insurance single price of 2,928 yuan. If patients need to apply immunotherapy, it is recommended to consult the oncology department of the hospital and apply the above immunological agents according to the specific conditions of the patients, do not use drugs blindly.